GlassScriptPhysician profile
Douglas D Yun
NPI 1487611679
$5,639.85
in general payments reported to CMS, 2019-2025
28 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $578 · 2021: $836 · 2022: $966 · 2023: $676 · 2024: $1,342 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,241.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $983.32 | 2019-2025 | |
| Amgen INC. | $740.33 | 2019-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $407.12 | 2019-2024 | Xarelto |
| Abiomed | $384.59 | 2020-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.98 | 2021-2024 | Jardiance |
| Abbott Laboratories | $323.03 | 2019-2024 | Aveir, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $316.95 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $260.31 | 2020-2025 | Farxiga, Wainua |
| Edwards Lifesciences Corporation | $231.73 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $230.99 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $220.79 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $205.60 | 2021-2024 | Verquvo |
| Medtronic, INC. | $152.41 | 2024 | Micra |
| Shockwave Medical, INC | $147.51 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amarin Pharma, INC. | $113.10 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $86.55 | 2021-2023 | Nexletol |
| Pfizer INC. | $84.57 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $79.29 | 2019-2021 | |
| Akcea Therapeutics, INC. | $74.15 | 2019-2020 | |
| Boston Scientific Corporation | $65.57 | 2024 | Emblem Mri S-Icd, Resonate El Icd Vr |
| Kiniksa Pharmaceuticals International, Plc | $30.81 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $24.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $23.10 | 2019 | |
| Scpharmaceuticals INC. | $21.44 | 2023 | |
| Novo Nordisk INC | $19.00 | 2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $18.00 | 2024 | |
| Philips North America LLC | $15.15 | 2024 | (5044) Mcot |
| Tactile Systems Technology INC | $14.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Yun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.